Disclosures for "Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results from the FENopta Trial Open-label Extension"
-
Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.
-
Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Jelena Drulovic has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hemofarm. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Actavis TEVSA. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Hemofarm. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medis. Jelena Drulovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zentiva. Jelena Drulovic has received research support from Ministry of Science, educaton and technological development of the Republic of Serbia.
-
Dr. Dufek has nothing to disclose.
-
The institution of Hrvoje Budincevic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viatris. The institution of Hrvoje Budincevic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbott. The institution of Hrvoje Budincevic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medis Adria. The institution of Hrvoje Budincevic has received research support from F. Hoffmann-La Roche Ltd. The institution of Hrvoje Budincevic has received research support from NovoNordisk. The institution of Hrvoje Budincevic has received research support from Celltrion.
-
Mario Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Mario Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Mario Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Mario Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Mario Habek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Mario Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mario Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mario Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Mario Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Astra Zeneca. An immediate family member of Mario Habek has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Mario Habek has received research support from Croatian Science Foundation.
-
Mrs. Caunt has received personal compensation for serving as an employee of Genentech. Mrs. Caunt has stock in Genentech.
-
Malgorzata Sierzega has stock in Roche.
-
David Clayton has received personal compensation for serving as an employee of Genentech/Roche. David Clayton has received stock or an ownership interest from Roche. An immediate family member of David Clayton has received publishing royalties from a publication relating to health care.
-
Dr. CHEN has nothing to disclose.
-
Dr. Ratchford has received personal compensation for serving as an employee of Genentech. Dr. Ratchford has stock in F. Hoffman La-Roche.
-
Dr. Goodyear has received personal compensation for serving as an employee of Genentech. Dr. Goodyear has received personal compensation for serving as an employee of Novartis. Dr. Goodyear has stock in Novartis. Dr. Goodyear has stock in Genentech.
-
Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for cabaletta. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech.